BridgeMD
YF_PROTECT: Prophylactic treatment with sofosbuvir for Yellow Fever
EU CTIS ID: 2024-510949-34-00
What this study is testing
To assess the effect of sofosbuvir on YF17D replication.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male and female sex
- Participants between 18 and 50 years
- Participants that are generally healthy without substantial comorbidities, especially no primary or secondary immunodeficiencies. Patients with chronic diseases other than those mentioned in the exclusion criteria below and which are stable, defined as not requiring change of therapy or hospitalization in the six weeks preceding study enrolment, may be eligible for this study. This will be decided by the researcher who is medically responsible.
You likely can't join if
- Previous yellow fever vaccination
- Documented primary or secondary immunodeficiencies
- Thymic disfunction (such as thymoma, thymectomy, thymic radiation treatment, myasthenia gravis or DiGeorge syndrome)
- Multiple sclerosis
- Pregnancy at time of inclusion (pregnancy test is performed at inclusion)
- Breastfeeding during the course of the study
See the full eligibility criteria
- Male and female sex
- Participants between 18 and 50 years
- Participants that are generally healthy without substantial comorbidities, especially no primary or secondary immunodeficiencies. Patients with chronic diseases other than those mentioned in the exclusion criteria below and which are stable, defined as not requiring change of therapy or hospitalization in the six weeks preceding study enrolment, may be eligible for this study. This will be decided by the researcher who is medically responsible.
- Previous yellow fever vaccination
- Documented primary or secondary immunodeficiencies
- Thymic disfunction (such as thymoma, thymectomy, thymic radiation treatment, myasthenia gravis or DiGeorge syndrome)
- Multiple sclerosis
- Pregnancy at time of inclusion (pregnancy test is performed at inclusion)
- Breastfeeding during the course of the study
- Known chicken-egg allergy
- Known hypersensitivity to any other of the vaccine components
- Participation in another clinical trial in which life-attenuated viruses are contraindicated and which might jeopardize participants safety
- Planned travel to a yellow fever endemic country within four months after start of the study
- Vaccination with other vaccines < 1 month before inclusion
- Use of anticoagulants
- Current use (or in previous 2 weeks) of p-glycoprotein / BCRP inducers such as rifampicin, seizure medication or St. John Wort plant extracts
- Use of antihyperglycemic drugs or documented diabetes mellitus
- Current use (or in previous 3 months) of amiodaron
- History of liver disease
- Documented end-stage kidney disease or eGFR <30ml/min
- Previous yellow fever infection
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.